Spotlight Innovation, Inc. has announced that subsidiary Caretta Therapeutics, LLC, has begun the process of manufacturing Venodol topical roll-on, a non-addictive alternative to opioid and steroidal analgesics intended to provide relief from chronic pain. The manufacturing of Venodol is taking place at facilities located in Florida.
Commenting on the start of the manufacturing process, John Krohn, Spotlight Innovation's President and Chief Executive Officer, said, "Commencing production is an exciting milestone in our efforts to bring Venodol to the commercial market. We believe there is significant demand for non-addictive remedies that have the potential to improve quality-of-life for the millions of people who suffer from chronic pain, and we are looking forward to offering Venodol to consumers in the near future."
Venodol topical roll-on is formulated to relieve chronic pain associated with inflammation, including joint pain, tendinitis, and arthritis (excluding osteoarthritis). Venodol is tentatively scheduled to be available in the United States in summer 2017. Caretta Therapeutics plans to introduce additional product formats formulated to provide non-addictive alternatives to opioid drugs for the relief of chronic pain.
According to the American Society of Addiction Medicine's Opioid Addiction 2016 Facts & Figures, in 2015, two million Americans 12 or older had a substance use disorder involving prescription pain relievers, and there were more than 20,000 accidental overdose deaths related to prescription pain relievers.